サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1795187

腫瘍誘発性骨軟化症の世界市場

Tumor-Induced Osteomalacia

出版日
ページ情報
英文 281 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.55円
腫瘍誘発性骨軟化症の世界市場
出版日: 2025年08月21日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 281 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

腫瘍誘発性骨軟化症の世界市場は2030年までに1億2,950万米ドルに達する見込み

2024年に1億1,450万米ドルと推定される腫瘍誘発性骨軟化症の世界市場は、2030年には1億2,950万米ドルに達し、分析期間2024-2030年のCAGRは2.1%で成長すると予測されます。本レポートで分析したセグメントの1つである医薬品＆サプリメント治療は、CAGR 2.5％を記録し、分析期間終了時には8,790万米ドルに達すると予測されます。外科治療分野の成長率は、分析期間中CAGR 1.2％と推定されます。

米国市場は3,120万米ドルと推定、中国はCAGR4.0％で成長予測

米国の腫瘍誘発性骨軟化症市場は、2024年に3,120万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに2,430万米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ0.8％と1.8％と予測されています。欧州では、ドイツがCAGR 1.2%で成長すると予測されています。

世界の腫瘍誘発性骨軟化症市場- 主要動向と促進要因のまとめ

腫瘍誘発性骨軟化症が内分泌学および腫瘍学で独自の課題となる理由とは？

腫瘍誘発性骨軟化症（TIO）は、腫瘍が過剰なFGF23を分泌し、リン酸喪失、弱い骨、慢性疼痛を引き起こす稀な疾患です。漠然とした症状や、この疾患の原因である小さくて成長が遅い腫瘍の位置を特定することが困難なため、診断が遅れることが多いです。

一旦腫瘍が同定されれば、通常は外科的に腫瘍を摘出することで症状は消失します。しかし、手術不可能な腫瘍や隠れた腫瘍の場合は、リン酸塩とビタミンDのサプリメントによる長期管理が必要となるが、完全な回復には不十分であることが多いです。

診断の革新と標的治療はTIO管理をどのように変えるか？

ソマトスタチン受容体を標的としたトレーサーを用いた画像診断の進歩により、腫瘍の局在が改善されつつあります。FGF23を測定する血液検査は、病気の診断と進行の追跡に不可欠となっています。

FGF23を阻害するモノクローナル抗体であるBurosumabは、切除不能症例に対する画期的な治療法です。リン酸値を回復させ、痛みを軽減し、運動能力を向上させ、手術が選択できない場合に的を絞った治療を提供します。

腫瘍誘発性骨軟化症市場の成長はいくつかの要因によって牽引される...

市場成長の原動力は、診断法の改善、認知度の向上、burosumabのような生物学的製剤の出現です。希少疾患調査への資金提供や政策的インセンティブの増加病院、研究機関、製薬企業間の協力体制が、この無視された分野に注目と革新をもたらしつつあります。

セグメント

治療（医薬品・サプリメント治療、外科治療）;エンドユース（病院エンドユース、外来外科センターエンドユース、専門クリニックエンドユース、その他エンドユース）

調査対象企業の例

  • Amgen Inc.
  • Amolyt Pharma
  • Ascendis Pharma A/S
  • Bayer AG
  • BridgeBio Pharma
  • Chugai Pharmaceutical Co., Ltd.
  • CRISPR Therapeutics
  • Debiopharm Group
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Visterra, Inc.（Otsuka subsidiary）

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP38263

Global Tumor-Induced Osteomalacia Market to Reach US$129.5 Million by 2030

The global market for Tumor-Induced Osteomalacia estimated at US$114.5 Million in the year 2024, is expected to reach US$129.5 Million by 2030, growing at a CAGR of 2.1% over the analysis period 2024-2030. Drugs & Supplements Treatment, one of the segments analyzed in the report, is expected to record a 2.5% CAGR and reach US$87.9 Million by the end of the analysis period. Growth in the Surgery Treatment segment is estimated at 1.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$31.2 Million While China is Forecast to Grow at 4.0% CAGR

The Tumor-Induced Osteomalacia market in the U.S. is estimated at US$31.2 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$24.3 Million by the year 2030 trailing a CAGR of 4.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.8% and 1.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.2% CAGR.

Global Tumor-Induced Osteomalacia Market - Key Trends & Drivers Summarized

Why Is Tumor-Induced Osteomalacia a Unique Challenge in Endocrinology and Oncology?

Tumor-Induced Osteomalacia (TIO) is a rare disorder where tumors secrete excess FGF23, causing phosphate loss, weak bones, and chronic pain. Diagnosis is often delayed due to vague symptoms and the difficulty of locating small, slow-growing tumors responsible for the condition.

Once identified, surgical removal of the tumor usually resolves symptoms. However, inoperable or hidden tumors require long-term management with phosphate and vitamin D supplements, which are often insufficient for full recovery.

How Are Diagnostic Innovations and Targeted Therapies Changing TIO Management?

Imaging advances using somatostatin receptor-targeted tracers are improving tumor localization. Blood tests measuring FGF23 have become essential for diagnosing and tracking disease progression.

Burosumab, a monoclonal antibody that blocks FGF23, is a game-changing therapy for non-resectable cases. It restores phosphate levels, reduces pain, and improves mobility, offering targeted treatment where surgery is not an option.

The Growth in the Tumor-Induced Osteomalacia Market Is Driven by Several Factors…

Market growth is driven by improved diagnostics, awareness, and the emergence of biologics like burosumab. Rare disease research funding and policy incentives are increasing. Collaborative efforts among hospitals, research institutions, and pharmaceutical companies are bringing more attention and innovation to this neglected segment.

SCOPE OF STUDY:

The report analyzes the Tumor-Induced Osteomalacia market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment (Drugs & Supplements Treatment, Surgery Treatment); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 44 Featured) -

  • Amgen Inc.
  • Amolyt Pharma
  • Ascendis Pharma A/S
  • Bayer AG
  • BridgeBio Pharma
  • Chugai Pharmaceutical Co., Ltd.
  • CRISPR Therapeutics
  • Debiopharm Group
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • Ionis Pharmaceuticals, Inc.
  • Kyowa Kirin Co., Ltd.
  • Merck & Co., Inc.
  • Novo Nordisk A/S
  • OPKO Health, Inc.
  • Pfizer Inc.
  • Radius Health, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceutical Inc.
  • Visterra, Inc. (Otsuka subsidiary)

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Tumor-Induced Osteomalacia - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Improved Diagnostic Imaging Capabilities Propel Early Detection of TIO-Causing Tumors
    • Emergence of Targeted Therapies like Burosumab Strengthens Clinical Outcomes in Unresectable TIO
    • Increased Physician Awareness and Education Initiatives Accelerate Diagnosis and Treatment Uptake
    • Expansion of Orphan Drug Development Programs Spurs Innovation in Rare Bone Disorder Therapies
    • Advances in FGF23 Assay Technologies Drive Precision Monitoring and Treatment Personalization
    • Supportive Regulatory Frameworks for Ultra-Rare Diseases Generate Opportunities for Niche Biopharma Players
    • Rising Investment in Musculoskeletal Disease Research Throws the Spotlight on TIO as a Clinical Priority
    • Development of Cross-Specialty Diagnostic Pathways Enhances Case Identification Rates
    • Growth in Genetic and Molecular Diagnostic Tools Supports Earlier Intervention in TIO
    • Patient Advocacy and Access Programs Sustain Long-Term Treatment Adherence and Market Viability
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tumor-Induced Osteomalacia Market Analysis of Annual Sales in US$ for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Tumor-Induced Osteomalacia by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Drugs & Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Drugs & Supplements Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Drugs & Supplements Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Surgery Treatment by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Surgery Treatment by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Specialty Clinics End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Specialty Clinics End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 29: Canada Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 30: Canada Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 31: Canada 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • JAPAN
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 35: Japan Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Japan Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 37: Japan 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 40: Japan 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • CHINA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 41: China Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 42: China Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 43: China 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 44: China Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 46: China 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • EUROPE
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 47: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 48: Europe Historic Review for Tumor-Induced Osteomalacia by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 49: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 52: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • FRANCE
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 56: France Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 57: France Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 58: France 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 59: France Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 61: France 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • GERMANY
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Germany Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 64: Germany 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 67: Germany 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Italy Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 70: Italy 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 73: Italy 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 75: UK Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 76: UK 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 77: UK Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 79: UK 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 80: Spain Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Spain Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 82: Spain 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 83: Spain Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Spain Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 85: Spain 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 86: Russia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Russia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 88: Russia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 89: Russia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Russia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 91: Russia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 92: Rest of Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Rest of Europe Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 94: Rest of Europe 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 95: Rest of Europe Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of Europe Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 97: Rest of Europe 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 98: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 99: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 100: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 101: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 103: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 107: Australia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Australia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 109: Australia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 110: Australia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Australia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 112: Australia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • INDIA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 113: India Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 114: India Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 115: India 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 116: India Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 117: India Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 118: India 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 119: South Korea Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 120: South Korea Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 121: South Korea 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 122: South Korea Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 123: South Korea Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 124: South Korea 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 125: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Rest of Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 127: Rest of Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 128: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Rest of Asia-Pacific Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 130: Rest of Asia-Pacific 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 131: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 132: Latin America Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 133: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 134: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Latin America Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 136: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 140: Argentina Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Argentina Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 142: Argentina 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 143: Argentina Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Argentina Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 145: Argentina 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 146: Brazil Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Brazil Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 148: Brazil 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 149: Brazil Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Brazil Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 151: Brazil 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 152: Mexico Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Mexico Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 154: Mexico 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 155: Mexico Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Mexico Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 157: Mexico 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 158: Rest of Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Rest of Latin America Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 160: Rest of Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 161: Rest of Latin America Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Rest of Latin America Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 163: Rest of Latin America 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 164: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2024 through 2030 and % CAGR
    • TABLE 165: Middle East Historic Review for Tumor-Induced Osteomalacia by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 166: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 167: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Middle East Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 169: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 173: Iran Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Iran Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 175: Iran 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 176: Iran Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Iran Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 178: Iran 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 179: Israel Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Israel Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 181: Israel 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 182: Israel Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Israel Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 184: Israel 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 185: Saudi Arabia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Saudi Arabia Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 187: Saudi Arabia 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 188: Saudi Arabia Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Saudi Arabia Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 190: Saudi Arabia 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 191: UAE Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 192: UAE Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 193: UAE 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 194: UAE Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 195: UAE Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 196: UAE 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 197: Rest of Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Middle East Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 199: Rest of Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 200: Rest of Middle East Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Middle East Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 202: Rest of Middle East 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030
  • AFRICA
    • Tumor-Induced Osteomalacia Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 203: Africa Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Africa Historic Review for Tumor-Induced Osteomalacia by Treatment - Drugs & Supplements Treatment and Surgery Treatment Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 205: Africa 16-Year Perspective for Tumor-Induced Osteomalacia by Treatment - Percentage Breakdown of Value Sales for Drugs & Supplements Treatment and Surgery Treatment for the Years 2014, 2025 & 2030
    • TABLE 206: Africa Recent Past, Current & Future Analysis for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Africa Historic Review for Tumor-Induced Osteomalacia by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ for Years 2014 through 2023 and % CAGR
    • TABLE 208: Africa 16-Year Perspective for Tumor-Induced Osteomalacia by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use, Specialty Clinics End-Use and Other End-Uses for the Years 2014, 2025 & 2030

IV. COMPETITION